NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

Core Viewpoint - NovaBridge Biosciences has appointed Dr. Emmett T. Cunningham, Jr. as Vice Chairman of the Board, which is expected to enhance the company's strategic direction and shareholder value through his extensive biopharma experience [1][3][7]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with agile clinical development to advance breakthrough assets [9]. - The company operates a unique hub-and-spoke business model aimed at bridging the gap between unmet patient needs and transformative care [3][7]. Leadership Appointment - Dr. Cunningham brings over 25 years of experience in biopharma, having held leadership roles in venture capital and major pharmaceutical companies, including Blackstone Group and Pfizer [2][5][6]. - His appointment is seen as a positive endorsement of NovaBridge's mission to create shareholder value by expediting the development of transformative medicines [7]. Research and Development Focus - Dr. Cunningham will also join the Research and Development Committee of the Board, which is established to expedite innovation and long-term growth [7]. - The company is currently developing several drug candidates, including givastomig and VIS-101, targeting various cancers and eye diseases [10][12]. Pipeline Highlights - Givastomig is a bispecific antibody being evaluated in a Phase 2 study for Claudin 18.2-positive gastric cancer, following positive results from a Phase 1b study [11]. - VIS-101 is in a Phase 2a study for wet age-related macular degeneration and diabetic macular edema, aiming to provide more durable treatment benefits [12].